Future CGT Manufacturing Trends, AI Reality Checks, and Phase 1 Strategy

This segment of Cell & Gene Live, How CGT Developers Can Choose the Right Manufacturing Model for Their Pipeline, features Omkar Kawalekar, Ph.D., Manufacturing & Supply Chain Lead, Deloitte Consulting and Zoe Zheng, Executive Director, Pipeline Technical and Strategic Lead, Legend Biotech discussing the innovations most likely to impact CGT commercialization, such as closed automated platforms that generate continuous process data, AI-driven faster analytics and predictive release, and digital orchestration that connects clinical scheduling, manufacturing, logistics, and quality in real time. The panelists also offer a reality check on AI and practical Phase 1 advice.